The impact of physical activity (PA) on lymphoma survival is not known. The association of PA and change in PA with overall (OS), lymphoma-specific (LSS) and event-free (EFS) survival was evaluated in a prospective cohort of newly diagnosed lymphoma patients (2002)(2003)(2004)(2005)(2006)(2007)(2008)(2009)(2010)(2011)(2012). We calculated Leisure Score Indexes (mLSI) from the self-reported usual adult PA (baseline) and at 3-years post-diagnosis (FU3), grouping patients by active vs insufficiently active by the American Cancer Society PA guidelines. Associations of PA with survival were assessed using hazard ratios (HRs) and 95% confidence intervals (CI) from Cox models stratified by lymphoma subtype, adjusted for age, sex, baseline BMI, and comorbidity score with change scores further adjusted for baseline PA. Three thousand sixty participants were evaluable at baseline and 1371 at FU3. Increasing PA after diagnosis is significantly associated with improved OS and LSS supporting an important role for PA in lymphoma survivorship and the need for intervention trials. 14 However, it is not known whether changes in PA after diagnosis can change lymphoma-specific outcomes in survivors.
| INTRODUCTION
It is estimated, as of January 1, 2016, there were 219 570 Hodgkin lymphoma (HL) and 686 370 non-Hodgkin lymphoma (NHL) survivors in the United States. 1 With an aging population and more effective therapies, the number of lymphoma survivors is expected to grow.
There is increasing evidence that healthy behaviors benefit cancer survivors by improving fatigue, functioning, quality of life (QOL), risk of long-term complications and survival. Increasing physical activity (PA) may not just increase overall survival (OS) but also decrease risk of cancer progression or relapse in patients with cancers of the breast, 2,3 prostate 4 and colon. [5] [6] [7] However, results from studies in solid tumor patients are difficult to extrapolate to lymphoma patients due to differences in disease biology, disease course, therapies utilized, and complications of treatment. † Priyanka A. Pophali and Andrew Ip contributed equally to this study.
Healthy lifestyle recommendations from hematology-oncology providers can be a strong motivation for lymphoma survivors to adopt positive lifestyle changes. 8 It is known from population-based studies that pre-diagnosis smoking, alcohol use, obesity and low Vitamin D levels adversely affect lymphoma outcomes. [9] [10] [11] [12] [13] Pre-diagnosis PA in diffuse large B-cell lymphoma (DLBCL) has been associated with improved survival outcomes. 14 However, it is not known whether changes in PA after diagnosis can change lymphoma-specific outcomes in survivors.
We hypothesized that (a) adults who are more physically active prior to and after lymphoma diagnosis have better lymphoma-related outcomes and (b) increasing the level of PA after lymphoma diagnosis can improve survival. Hence, we studied the association of selfreported usual adult PA, PA at 3 years after diagnosis and change in PA after diagnosis on OS, lymphoma-specific (LSS) and event-free survival (EFS) in a prospectively enrolled cohort of newly diagnosed patients with lymphoma.
| PATIENTS AND METHODS

| Study cohort
Full details of the Lymphoma SPORE Molecular Epidemiology
Resource (MER), a prospective cohort study of newly diagnosed lymphoma patients aged 18 years and older, have been previously described. 15 This analysis includes participants from the Mayo Clinic in Rochester, Minnesota, who were also enrolled in a companion study of lymphoma etiology from September 1, 2002 through December 31, 2012. 16 At enrollment, participants completed a baseline health and a self-administered risk factor questionnaire (RFQ).
The RFQ was part of the etiology study and included items on usual adult exercise, smoking, alcohol use and diet prior to the diagnosis of lymphoma. Pathology was reviewed by a hematopathologist and classified based on the WHO criteria. 17, 18 Study personnel abstracted baseline clinical data and initial course of therapy. Responses from the MER cohort baseline questionnaire were used to calculate a baseline co-morbidity score, assigning 1 point each for the following selfreported conditions: other cancer diagnosis within 3 years of lymphoma diagnosis (except nonmelanoma skin cancer), coronary artery disease, congestive heart failure, diabetes, hip fracture, hepatitis, autoimmune disease, and elevated creatinine.
All participants were contacted every 6 months for the first 3 years after diagnosis, and then annually thereafter to update health status.
Disease recurrence or progression, new therapies, and new cancers were validated against medical records. For decedents, death certificates and medical records were reviewed by study physicians to assign cause of death. At 3 years after diagnosis, a survivorship questionnaire (FU3) that included items on PA, smoking, alcohol, and diet was sent to all participants. This was an observational study and patients received care at provider discretion with no specific PA intervention.
Participants were considered evaluable at baseline if they had completed baseline RFQ, including questions on usual adult PA. They were considered evaluable at FU3 if they had been evaluable at baseline and completed the FU3 questionnaire, including the Godin Leisure Time Exercise Questionnaire (Godin). 15 In order to minimize the effect of occult lymphoma recurrences on PA levels, patients who had events (disease recurrence, re-treatment or death) 6 months before or after FU3 were excluded from the FU3 and PA change analysis (CONSORT diagram Supporting Information S1).
| Assessment of physical activity
On the baseline RFQ, participants were asked "During most of your adult life, how often did you do strenuous/moderate/light exercise?" The questions listed examples of exercise by intensity and asked patients to exclude walking outside the home and PA associated with jobs. Participants answered on a 6-point frequency scale ranging from "rarely or never" to "5 or more days per week". At FU3, participants completed the Godin, a validated tool for measuring PA in oncology patients 19 (Supporting Information S2). At FU3, participants also reported their perceived change in level of PA since lymphoma diagnosis by answering "How has your level of PA changed since your diagnosis of lymphoma or leukemia?" as no change, decreased or increased level of activity.
| Statistical analyses
We used PA data from the questionnaires to calculate a score corresponding to the Godin Leisure Score Index (LSI), which is a weighted summary measure of the frequency of self-reported weekly leisure-time exercise (times/week) calculated as (9 × strenuous activity) + (6 × moderate activity) + (3 × light activity) expressed in arbitrary units. 19 On the Godin, a moderate-to-strenuous LSI of ≥24 is used to classify cancer survivors into active and insufficiently active categories as per the American Cancer Society guidelines (≥ 150 minutes of moderate to vigorous PA per week). 20 Although the RFQ did not have the specific Godin questions, we used the data on frequency, duration and intensity of PA to derive a modified LSI (mLSI). mLSI was modeled as a continuous score (per 10-point change) and by tertile. mLSI change was calculated as baseline mLSI subtracted from FU3 LSI. Survival was measured as time from diagnosis (for baseline PA) and time from FU3 (for FU3 PA and PA change from baseline to FU3 PA) until death due to any cause and due to lymphoma. For event analysis beyond FU3, participants who had an event prior to FU3 were excluded. We evaluated the association of PA with outcome using Kaplan-Meier curves as well as hazard ratios (HRs) and 95% confidence intervals (CI) from Cox models stratified by lymphoma subtype. All Cox models were adjusted for age, sex, baseline BMI, and comorbidity score. The PA change models were also adjusted for baseline PA. Subset analyses stratified on age, body mass index (BMI), histological subtype, event free survival at 36 months (EFS36, defined as any lymphoma recurrence, complication due to lymphoma, or death due to lymphoma) and treatment status were also assessed. All statistical analyses were conducted using SAS 9.4 (SAS Institute, Cary, NC).
3 | RESULTS
| Usual PA prior to diagnosis and subsequent survival
From 2002 to 2012, 4087 participants were enrolled in the MER at the Mayo Clinic, and of these, 3129 participants completed a RFQ, of which 3060 were evaluable for usual level of PA prior to diagnosis (baseline mLSI). The baseline characteristics of the evaluable patients are shown in Table 1 . Compared to the participants who were evaluable for mLSI (N = 3060), the 1027 participants enrolled but not evaluable for mLSI were more likely to be male (65% vs 58%), have aggressive histology (44% vs 37%), ECOG performance status ≥2
(9% vs 5%), obesity (BMI ≥30, 35% vs 29%) and missing co-morbidity data (31% vs 20%) (Supporting Information Table S3 ). At baseline, the median mLSI was 28 (IQR 13-43); 1392 (46%) of patients could be classified as active (mLSI ≥24). Correlates of level of usual adult mLSI (active vs insufficiently active) are shown in Supporting Information Table S4 . Participants who were active had a lower median BMI and sufficient Vitamin D levels than those who were insufficiently active based on mLSI, else were similar on other factors.
At a median follow-up of 8.9 years from diagnosis, there were 863 total deaths, 440 of which were attributable to lymphoma. Sur- 
| PA at FU3 and subsequent survival
Of 3060 participants with a baseline LSI, 368 died prior to FU3 and 93 who had an event within 6 months of FU3 were excluded. Baseline characteristics for those evaluable (N = 1371, Table 1 ) and not evaluable (N = 1228) for LSI at FU3 were comparable, except that comorbidity information was more likely to be missing (26% vs 14%) in those not evaluable (Supporting Information Table S3 ). At FU3, the median LSI at FU3 was 23 (IQR 9-40); 544 (40%) of patients were classified as active (LSI ≥ 24). Compared to the insufficiently active, FU3 survivors who were active were more likely to be younger, male, have aggressive lymphoma histology, lower BMI, fewer co-morbidities and higher baseline mLSI (Supporting Information Table S4 ). For EFS analysis beyond FU3, participants who had an event prior to FU3
(N = 267) were excluded and only participants who achieved EFS36
(N = 1104) were included. a MER co-morbidity score components (1 point each): other cancer diagnosis within 3 years of lymphoma diagnosis (except non-melanoma skin cancer), coronary artery disease, congestive heart failure, diabetes, hip fracture, hepatitis, autoimmune disease, and elevated creatinine. Missing co-morbidity score was used as a category for adjustment of Cox models. 
| Sub-group analysis
In order to determine if the survival benefit from increasing PA was specific to any particular subgroup of patients, analyses by age (<60 vs ≥60 years), sex (male vs female), BMI (<30 vs ≥30), co-morbidity score (0 vs ≥1 vs missing), disease histology (aggressive vs indolent;
individual subtypes DLBCL, CLL, and FL), patients with and without events by FU3 (EFS36 achievers vs non-achievers), and any treatment versus no treatment by FU3 were performed. These results showed superior OS, LSS and EFS were consistently associated with higher mLSI at baseline and higher LSI at FU3 among all the subgroups analyzed (not shown). Figure 3 illustrates the subgroup analysis for change in mLSI from baseline to FU3 demonstrating a consistent survival benefit from increasing PA among all the lymphoma survivors. The strengths of our study include prospective enrollment and follow-up of participants; detailed clinical data; measurement of PA at enrollment and at FU3, allowing assessment of change; ability to adjust for important potential confounding factors including level of comorbidity and BMI; and the length of follow-up. We do acknowledge several limitations. PA was self-reported, and thus is susceptible to measurement error, especially reporting of usual adult PA prior to diagnosis, which could be impacted by severity of lymphoma at enrollment. Further, we did not have the specific Godin questions for assessment of usual adult PA prior to diagnosis, as the Godin assesses PA in the past week; however, we were able to use data on frequency, duration and intensity of PA to develop a surrogate of the LSI. We also had many participants without available PA measurements at both enrollment and at FU3. While the differences between those with and without PA data at baseline are possibly affected by patients undergoing active work-up and management, we did not observe major differences in those with and without PA data at FU3. The calculated mLSI and self-perceived PA change results broadly paralleled each other even though they measured PA differently. While the change in PA provide compelling data to increase PA to improve outcomes in lymphoma patients, these observational data could be impacted by selection bias and unmeasured confounding factors, and the impact of a PA intervention needs to be addressed using a randomized clinical trial study design.
Survivorship guidelines as well as evidence for the role of health behaviors in lymphoma survivors are limited. 21 The only randomized clinical trial of exercise in lymphoma studied 122 patients in Canada, 22 with focus on physical functioning and QOL as study end points.
Investigators randomized lymphoma patients on or off chemotherapy show a nonsignificant trend toward progression free survival benefit. 23 To our knowledge, our study is the first to measure the effect of change in PA after lymphoma diagnosis on subsequent OS and LSS.
Recently, Boyle et al. reported that higher pre-diagnosis PA was asso- The mechanism by which PA affects OS in lymphoma patients may be explained in part by decreased cardiovascular events as is well established in the non-cancer population. 24 Jones et al. studied 1187 adult survivors of pediatric HL and found that vigorous intensity exercise was associated with a lower risk of cardiovascular events in a dose-dependent manner independent of cardiovascular risk profile and HL treatment. 25 The mechanism of disease-specific survival benefit from PA is likely multifactorial and not well understood. 26, 27 One possible explanation could be that patients who are more physically active are more likely to tolerate and complete lymphoma treatments. 23 Other explanations might include changes in metabolism, sex hormones, Vitamin D levels, angiogenesis, and immune function, although these have been mainly studied in breast or colorectal cancer patients to date. 12,13,28-31 Very few studies have examined the effect of PA on lymphoma biology, although there is a suggestion in animal models that tumor progression is retarded with PA via and interventional studies will need to be performed in this population.
Cancer survivors commonly ask what they can do to decrease the risk of recurrence or progression. Our study strongly suggests that providers should counsel patients on the important role for PA in lymphoma survivorship. Many efforts have been undertaken to improve upon the outcomes following standard chemotherapy in NHL, particularly in DLBCL, the most common subtype. With the exception of consolidative radiotherapy in bulky disease, most of these efforts have proven unsuccessful. 39 Herein, we found that PA is associated with improved overall and lymphoma-specific survival. These data provide a strong rationale for further investigating the role of PA in the care of lymphoma patients through intervention trials. Our study supports current national exercise guidelines for lymphoma survivors and suggests a benefit with even a modest increase in PA for those who cannot meet the guideline thresholds. Future studies are needed to elucidate the underlying biologic mechanisms as well as overcome barriers to effective delivery of exercise interventions to lymphoma patients.
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